Investment analysts at Wolfe Research assumed coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports. The brokerage set an "outperform" rating and a $29.00 price target on the stock. Wolfe Research's price objective indicates a potential upside of 20.73% from the stock's current price.
Several other analysts also recently weighed in on KMTS. Piper Sandler began coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued an "overweight" rating and a $27.00 price objective on the stock. Wells Fargo & Company started coverage on Kestra Medical Technologies in a research report on Monday. They issued an "overweight" rating and a $28.00 target price on the stock. The Goldman Sachs Group assumed coverage on Kestra Medical Technologies in a report on Monday. They set a "neutral" rating and a $24.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Kestra Medical Technologies in a research report on Monday. They set a "buy" rating and a $28.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Kestra Medical Technologies has a consensus rating of "Moderate Buy" and an average target price of $27.67.
Get Our Latest Stock Analysis on Kestra Medical Technologies
Kestra Medical Technologies Stock Performance
KMTS traded down $1.68 during trading on Monday, reaching $24.02. 217,488 shares of the company were exchanged, compared to its average volume of 285,081. Kestra Medical Technologies has a 52 week low of $20.00 and a 52 week high of $26.06.
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Recommended Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
